Abstract
The genetic alterations frequently involved in glial malignancies are in the tumor suppressor genes, Rb and p53. An altered Rb expression or p53 overexpression is thought to indicate defective tumor suppression and subsequently more aggressive tumors. Therefore, to assess the alterations in the conjoint expression of Rb and p53 proteins in formalin fixed paraffin embedded sections, 64 astrocytic tumors were studied (16 astrocytomas, 7 gemistocytic astrocytomas, 19 anaplastic astrocytomas and 22 glioblastomas) using the avidin biotin immunoperoxidase technique. Fifty two cases (81.25%) were found to be positive for p53 protein. Seventeen of these showed aberrant heterogenous staining for pRb, of which 7 were glioblastomas. Only one case of astrocytoma showed aberrant expression of both p53 and Rb. Thus, of the 64 tumors, simultaneous aberrant expression of both p53 and Rb was seen in 21.9% of cases. This was more commonly observed among glioblastoma cases (7/22). No statistical difference was found between the survival rate of heterogenous pRb and p53 positivity in different grades of tumors. In glioblastomas, the survival rate appeared to be less in patients expressing heterogenous pRb, but this was not statistically significant. These results lead us to suspect that p53 and pRb pathways are inactivated, either through mutation or as part of the neoplastic process in astrocytic tumors.
Similar content being viewed by others
References
Aka K, Barner JM, Bondy ML, et al: Detection of p53 alterations in human astrocytomas using frozen tissue sections for the polymerase chain reactions. J Neurooncol 16:125–133, 1993.
Bourne JA: Handbook of immunoperoxidase staining methods. Dako corporation, USA, 1983, p17.
Buckovich K, Duffy LA, Harlow D: The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58:1097–1105, 1989.
Cavenee WK, Dryja TP, Philips RA, et al: Expression of recessive allele by chromosomal mechanisms in retinoblastoma. Nature 305:779–784, 1983.
Collins VP, James CD: Gene and chromosomal alterations associated with the development of human gliomas. FASEB J 7:926–930, 1993.
Cordon-Cardo C: Mutation of cell regulators. Biological and clinical implications for human neoplasia Am J Pathol 147:545–560, 1995.
Cordon-Cardo C, Wartinger D. Petrylak D, et al: Altered expression of the retinoblastoma gene product: Prognostic indicator in bladder cancer. J Natl Cancer Inst 84:1251–1256, 1992.
Ellison DW, Gatter KC, Steart PV, et al: Expression of the p53 protein in a spectrum of astrocytic tumors. J Pathol 168:383–386, 1992.
Fults D, Brockmeyer D, Tullous MW, et al: p53 mutation and loss of heterozygosity on chromosome 17 and 10 during human astrocytoma progression. Cancer Res 52:674–679, 1992.
Haapasalo H, Isola J, Sa P, et al: Aberrant p53 expression in astrocytic neoplasma of the brain. Association with proliferation. Am J Pathol 142:1347–1351, 1993.
Hamel W, Westphal M, Shepard HM: Loss in expression of the retinoblastoma gene product in human gliomas is associated with advanced disease. J Neuro oncology 16:159–165, 1993.
Hansen MF, Koufos A, Gallie BL, et al: Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci USA 82:6216–6220, 1985.
He J, Jeffrey JO, James CD: Lack of p16 INK4 or Retinoblastoma protein (pRb) or amplification associated over expression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 55:4833–4836, 1995.
Henson JW, Schnitker BL, Lorrea KM, et al: The retinoblastoma gene is involved in malignant progression of Astrocytomas. Ann Neurol 36:714–721, 1994.
Hesketh R: The oncogene handbook. Academic Press, California, 1994, p526.
Ichimura K, Schmidt EE, Loike HM, et al: Human glioblastomas with an alteration of the CDKN2A (p16 INK4A, MTS1) and CDK4 gene have frequent mutations of the retinoblastoma gene. Oncogene 13:1065–1072, 1996.
Ishikawa J, Xu H.J, Hu S-X, et al: Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res 51:5736–5743, 1991.
Iuzzolino P, Ghimenton C, Nicolato A, et al: p53 protein in low-grade astrocytomas: a study with long-term follow-up. Br J Cancer 69:586–591, 1994.
Jahnson S, Risberg B, Korlsson MG, et al: p53 and Rb immunostaining is locally advanced bladder cancer: Relation to prognostic variables and predictive value for the local response to radical radiotherapy. Eur Uro 28:135–142, 1995.
Karpeh MS, Brennass MF, Canee WG, et al: Altered patterns of retinoblastoma gene product expression in adult soft tissue sarcomas. Br J Cancer 72:986–991, 1995.
Kleihues P, Burger PC, Scheithauer BW: Histological typing of tumors of the central nervous system. International classification of tumors No. 21, 2nd edn. World Health Organization, Geneva, 1993.
Lee WH, Shew JY, Hong FD: The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 329:642–645, 1987.
Lee SH, Kim JH, Rhee CH, et al: Loss of heterozygosity on chromosome 10, 13q (Rb), 17p and p53 gene mutations in human brain gliomas. J Korean Med Sci 10:442–448, 1995.
Levine AJ: The tumor suppressor genes. Ann. Rev. Biochem 62:623–651, 1993.
Louis DN, von Deimling A, Chung RY: Comparative study of p53 gene and protein alterations in human astrocytomas. J Neuropathol Exp Neurol 52:31–38, 1993.
Mihara K, Cao X-R, Yen A, et al: Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product. Science 246:1300–1303, 1982.
Nakamura M, Konishi N, Tsunoda S, et al: Immunohistochemical evaluation of pRb, p16, INK4 and cyclin D1 as a prognostic factor in astrocytic tumors (Abst) J Neurooncol 30:111, 1996.
Rasheed ABK, Mchendon RE, Herndon JE, et al: Alterations of the TP53 gene in human gliomas. Cancer Res 54:1324–1330, 1994.
Trudel M, Mulligass L, Cavenee WK, et al: Retinoblastoma and p53 gene product expression in breast carcinoma: Immunohistochemical analysis and clinicopathologic correlation. Human Pathol 23:388–1394, 1992.
Tsuzuki T, Tsunoda S, Sakaki T, et al: Alterations of retinoblastoma, p53, p16 (CDKN2), and p15 genes in human astrocytomas. Cancer 78:287–293, 1996.
Watanabe K, Tachibana O, Yonekawa Y, et al: Role of gemistocytes in astrocytoma progression. Lab Invest 76:277–284, 1997.
Whyte P, Buchkovich KJ, Horowitz JM, et al: Association between an oncogene and an anti-oncogene: the adenovirus EIA proteins bind to the retinoblastoma gene product. Nature 334:124–129, 1988.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rathore, A., Kamarajan, P., Mathur, M. et al. Simultaneous alterations of retinoblastoma and p53 protein expression in astrocytic tumors. Pathol. Oncol. Res. 5, 21–27 (1999). https://doi.org/10.1053/paor.1999.0021
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1053/paor.1999.0021